Boston Scientific has acquired American Medical Systems’ (AMS) men’s health and prostate health businesses from Endo International for $1.6bn in cash.

Announced in March this year, the deal also requires Boston Scientific to make an additional payment of $50m based on sales in 2016.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The acquired portfolio includes GreenLight XPS and HPS Laser Therapy systems designed to treat benign prostatic hyperplasia, AMS 800 Urinary Control system for male incontinence and AMS 700 Inflatable Penile Prosthesis used for erectile dysfunction.

"Our combined organisation will bring value-driven innovations that can help healthcare providers advance patient outcomes, reduce procedure costs and enhance quality."

According to Boston Scientific, AMS’ women’s health business was not included in the deal.

Boston Scientific urology and pelvic health president Karen Prange said: "Together, we create a business with nearly $1bn in annual sales, strong future growth prospects through innovation and market expansion, and a significant opportunity to address unmet medical needs.

See Also:

"As a category leader, our combined organisation will bring value-driven innovations that can help healthcare providers advance patient outcomes, reduce procedure costs, enhance quality and evolve the treatment of urologic and pelvic conditions in ways that previously could not be realised by either company alone."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company is expected to incorporate the acquisitions in its urology and women’s health businesses. The joint entity will be called Boston Scientific Urology and Pelvic Health business.

This business unit will continue to invest in surgical solutions for the treatment of abnormal uterine bleeding and uterine fibroids.

These new technologies complement Boston Scientifics’ urology portfolio to treat kidney stones and pelvic floor disorders, enabling further innovation for the company across five common urologic diseases that account for 50% of all urologic surgical procedures.